Kodiak Sciences/$KOD
1D1W1MYTD1Y5YMAX
Capital at risk
About Kodiak Sciences
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
- Ticker
- $KOD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 141
- Headquarters
- Palo Alto, United States
- Website
- kodiak.com
Kodiak Sciences Metrics
BasicAdvanced
$2.1B
-
-$4.18
2.20
-
Price and volume
Market cap
$2.1B
Beta
2.2
52-week high
$47.84
52-week low
$9.10
Average daily volume
598K
Financial strength
Current ratio
2.489
Quick ratio
2.386
Long term debt to equity
0.703
Total debt to equity
0.863
Profitability
EBITDA (TTM)
-230.978
Management effectiveness
Return on assets (TTM)
-60.45%
Return on equity (TTM)
-368.37%
Valuation
Price to book
33.86
Price to tangible book (TTM)
33.86
Price to free cash flow (TTM)
-11.956
Free cash flow yield (TTM)
-8.36%
Free cash flow per share (TTM)
-2.759
Growth
Earnings per share change (TTM)
10.13%
3-year earnings per share growth (CAGR)
-9.87%
What the Analysts think about Kodiak Sciences
Analyst ratings (Buy, Hold, Sell) for Kodiak Sciences stock.
Analyst projections of the future price of Kodiak Sciences stock.
Bulls say / Bears say
Positive Phase 3 GLOW2 topline results showed Zenkuda (tarcocimab) superiority over sham in diabetic retinopathy—62.5% vs 3.3% achieving ≥2-step DRSS improvement and an 85% reduction in sight-threatening complications—de-risking the tarcocimab program and supporting a multi-indication BLA-ready profile. (Form 8-K)
Kodiak remains on track for September 2026 topline results from the Phase 3 DAYBREAK study evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, representing the next critical readout for its ABC platform pipeline. (Reuters)
The company completed enrollment of the first 300-patient cohort in its registrational Phase 3 PEAK study of KSI-101 in macular edema secondary to inflammation, with topline pivotal data expected in December 2026, further bolstering its late-stage pipeline. (Reuters)
Kodiak reported a widening second-quarter net loss of $65.6 million (-$1.05 per share) vs $54.3 million year-over-year, missing analyst estimates and triggering a 5.2% stock decline in after-hours trading. (Reuters)
Cash and cash equivalents fell to $125.9 million at June 30, 2026, down from $209.9 million at year-end 2025, raising concerns over runway adequacy and potential dilution ahead of key trial readouts. (Reuters)
Research and development expenses jumped to $56.1 million in Q2 2026 from $42.8 million a year earlier, underscoring a high burn rate that may intensify financing pressures. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
Kodiak Sciences Financial Performance
Revenues and expenses
Kodiak Sciences Earnings Performance
Company profitability
Upcoming events
No upcoming events
Kodiak Sciences News
AllArticlesVideos
Funds containing Kodiak Sciences
AllUSDGBPEUR
Fund name | Fund size | $KOD weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.14% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.14% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.